Get the latest content and program updates via The Insider from Life Time. As a thank you, get 20 percent off your next $100-plus purchase of Life Time supplements.
The controversy surrounding the FDA’s approval of the first new Alzheimer’s drug in nearly two decades will do little to temper demand by desperate patients and their caregivers. It may also exacerbate racial disparities among those vying for the treatment.
Memories of a former colleague — and recent research — remind me that an upbeat view of aging may pay healthy dividends well into our later years.
The latest thinking on Alzheimer’s disease suggests we may slow its development with diet and lifestyle shifts, but a recent harrowing experience has me wondering whether my brain is already too far gone — or if I just need to pay better attention to what I’m doing.
With computer access and capabilities often standing in the way of elderly Americans trying to sign up for the COVID-19 vaccine, a little patience — and perspective — can really come in handy.